Prostate Cancer
Conditions
Brief summary
The purpose of this study is to find out the effects (good and bad) of using newer technologies that allow very precise delivery of radiation. These newer technologies are Intensity Modulated Radiation Therapy (IMRT) and Image Guided Radiation Therapy (IGRT).
Detailed description
In this study the treating physicians will deliver a high dose of radiation to pelvic lymph nodes of 56 Gy (Gy/Gray = measure of amount of radiation) and at the same time give a boost (additional) radiation to the prostate itself (to 70 Gy). The study will evaluate the response of the cancer and side effects of radiation to pelvic lymph nodes and to the prostate. It is hoped that these newer technologies will: 1. allow a higher daily dose of radiation to the tumor and pelvic nodes 2. avoid nearby normal tissue and organs like the rectum and bladder 3. prevent the cancer from spreading or coming back
Interventions
RADIATIONRadiation Therapy
A high dose of radiation to the pelvic lymph nodes of 56 Gy (Gy/Gray = measure of amount of radiation) and at the same time give a boost (additional) radiation to the prostate itself (to 70 Gy).
Sponsors
Medical College of Wisconsin
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically confirmed, adenocarcinoma of the prostate * T1-2N0M0 with risk of pelvic lymph nodes involvement \>25% by Roach formula \[(2/3xPSA) + (Gleason Score - 6)x10\], or any T3-4N0M0 * Karnofsky Performance Scale \> 70. * Prostate tumor biopsy grading by Gleason score classification is mandatory prior to registration. * No prior pelvic or prostate radiation or chemotherapy for any reason; induction hormonal therapy prior to registration is acceptable. * Patients must sign a study-specific consent form prior to registration. * No evidence of distant metastases (Bone scanning)
Exclusion criteria
* Clinical or pathological evidence of distant metastases (M1). * Radical surgery for carcinoma of the prostate * History of prior chemotherapy * History of prior pelvic radiation therapy * Children (age \< 18).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change from baseline PSA level | 4 months | PSA level in blood is measured in units of nanograms per milliliter. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORWilliam Hall, MD
Medical College of Wisconsin
Outcome results
None listed